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“Valproic acid is an anticonvulsant 
drug with established activity in 
controlling seizures in glioma 
patients.”
Valproic acid (VPA) is an anticonvulsant 
drug with established activity in control-
ling seizures in glioma patients [1–2]. The 
mechanisms of the antiepileptic activity 
of VPA are well known [3]: enhancement 
of the inhibitory effects of the neuro-
transmitter GABA, blockage of the volt-
age-gated sodium channels and T-type 
calcium channels, attenuation of NMDA-
mediated excitation and alteration of fir-
ing frequency of neurons. VPA is exten-
sively bound to plasma proteins (>90%), 
mainly to plasma albumin, and the extent 
of binding decreases with increasing drug 
concentrations. VPA easily penetrates the 
blood–brain barrier: mechanisms involve 
both passive diffusion and bidirectional 
carrier-mediated transport via an anion 
exchanger at the brain capillary endothe-
lium. Cerebrospinal fluid (CSF) concen-
trations vary between 1 and 10% of total 
plasma concentrations. Active transport 
mediates the uptake of VPA into neuronal 
and glial cells, which results in intracellular 
concentrations that are higher than inter-
stitial fluid concentrations. This transport 
notably depends on monocarboxylate 
transporter 1, a membrane protein that 
is overexpressed in gliomas in correlation 
with histological grade. VPA is categorized 
as a nonenzyme-inducing antiepileptic 
drug (non-EI AED), and slightly inhib-
its CYP450 (CYP) isoenzymes. Through 
CYP inhibition, it can decrease the rate of 
metabolism of nitrosoureas and increase 
hematological toxicity. Moreover, VPA has 
been shown to decrease the clearance of 
temozolomide.
Approximately 30–50% of glioblastoma 
patients experience seizures, and patients 
with seizures could have a better progno-
sis than those without seizures: this has 
raised questions about whether the AEDs 
play some antitumor activity [4–5]. In this 
regard, VPA exhibits some pharmacody-
namic properties, that are unrelated to the 
antiepileptic activity, and preclinical stud-
ies have reported that the drug could affect 
tumor cells in many respects (inhibition of 
proliferation and angiogenesis, promotion 
of apoptosis and autophagy) [6]; however, 
the mode of action of VPA is enigmatic, 
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and the effects on glioma cells are somewhat 
contradictory [7–8].
VPA could exert an antineoplastic action 
mainly as a histone deacetylase (HDAC) inhibi-
tor, resulting in a chromatin decondensation 
and a better access of transcription factors and 
the translation machinery to DNA. VPA has 
been shown to inhibit HDAC 1 and 2 within 
clinically relevant concentrations. However, 
compared with other HDAC inhibitors (vori-
nostat, sodium butyrate, benzamides, depsipep-
tide), VPA is a relatively weak HDAC inhibitor.
VPA has DNA-demethylation properties, 
with either potentially positive antitumor 
effects, such as upregulation of several tumor 
suppressor genes and apoptosis inducer tran-
scripts (p21, p27, Bax, PTEN) or negative 
effects, such as an increased expression of 
MGMT RNA. Other mechanisms, potentially 
involved in an antitumor effects of VPA in 
preclinical models of gliomas, such as GABA 
increase, inhibition of L- and T-type calcium 
channels and GSK-3β inhibition, remain to be 
elucidated.
VPA has been shown to inhibit the prolif-
eration of glioma cells through several direct 
effects (inhibition of HDAC, p21 and NF-kB 
transcriptional activity); however, the in vitro 
effects of VPA are weak and largely variable 
depending on cell-line, dose and time of expo-
sure. Paradoxically, submillimolar concentra-
tions of VPA could enhance the proliferation 
of some glioma cell lines.
The effects of VPA on glioma cell differentia-
tion are also contradictory. Higher concentra-
tions of VPA enhance the expression of glial 
fibrillary acidic protein (GFAP) and promote 
the adoption of a glial phenotype in rat C6 gli-
oma cells while reducing their proliferation and 
migration capacities. Conversely, VPA has been 
shown to increase the expression of CD133, a 
stem cell marker, in some glioblastoma cell 
lines.
More convincing are the preclinical data sug-
gesting a synergistic effect of VPA with radio-
therapy and/or chemotherapy. VPA could inter-
fere with the DNA repair, thus enhancing the 
radiosensivity of malignant glioma cells while 
showing some radioprotective properties on 
normal brain tissue [9–10]. The combination of 
VPA and temozolomide (TMZ) displayed a sig-
nificantly enhanced antitumor effect in TMZ-
resistant malignant glioma cells, and this poten-
tiation was correlated with a VPA-mediated 
reduction of the expression of MGMT [11] 
which plays an important role in cellular resist-
ance to alkylating agents. The combination of 
VPA, TMZ and RT has been reported to cause 
a significant radiation enhancement, without 
antagonizing the cytotoxic effects of TMZ [12]. 
Recently, an additive, rather than synergis-
tic, effect when VPA, radiation and TMZ are 
combined has been reported [13].
Some retrospective clinical studies [4,14–16] 
and a meta-analysis of individual patient 
data [17] have suggested that VPA could pro-
long overall survival in adult patients with 
GBM. Oberndorfer and collegues [4] investi-
gated the effects of EI-AEDs or non-EIAEDs 
on survival in 168 patients with GBM treated 
with surgery, radiotherapy and chemotherapy 
(either CCNU or TMZ). A mild statistically 
significant difference in survival was observed 
between patients receiving a non-EI AED (13.9 
months) and those receiving an EI-AED (10.8 
months). Weller and colleagues [14] assessed 
the association of AED use and survival within 
the EORTC/NCIC temozolomide trial on 573 
patients with GBM. Patients receiving VPA 
alone (16.9%) appeared to derive more survival 
benefit from TMZ/RT than patient receiving 
an EI-AED only (44.6%) or patient not receiv-
ing any AED. No significant difference in terms 
of PFS was observed. In the study performed by 
Kerkhof et al. [16] patients with GBM using VPA 
in combination with TMZ/RT showed a longer 
median survival of 69 weeks compared with 61 
weeks in the group without VPA after adjusting 
for age, extent of resection and MGMT methyl-
ation status. Another study [15] has reported that 
VPA use during RT for GBM was associated 
with improved OS, independently of RTOG, 
RPA class, seizure history and concurrent TMZ 
use. Unfortunately, a recent meta-analysis on 
1869 patients enrolled in five Phase III trials on 
newly diagnosed GBM has failed to show any 
improvement of PFS and OS with the addition 
of VPA to standard chemoradiation [18].
In summary, some considerations are needed. 
All the available clinical studies carry impor-
tant limitations, in particular the retrospective 
design and the heterogeneity in terms of dose 
and duration of VPA administration. Moreover, 
VPA could effectively modify the biologic tar-
get in some, but not all, patients [19]. Only a 
Phase III trial, comparing in newly diagnosed 
GBM VPA in addition to chemoradiation versus 
chemoradiation alone, could definitively clarify 
“Approximately 30–50% of 
glioblastoma patients 
experience seizures...”
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the role of VPA as an antineoplastic agent. In 
the meantime, we do not encourage the choice 
of VPA as an antiepileptic drug in patients 
with seizures based on the potential antitumor 
activity only.
For the future, recently discovered common 
pathways of epileptogenesis and tumor growth 
in gliomas [20] hold promise as potential tar-
gets of therapy, and need to be investigated in 
adequately designed clinical trials.
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